ALTERATION OF VHL GENE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Blocks of preparations from 22 patients with metastatic renal cell carcinoma on target therapy were studied. The patients were examined for mutations/methylation of VHL gene. The mutations were detected in 10(45.5%) of 22 patients, VHL methylation was found in 1 (4.5%) patient. Overall survival was 36.4 and 66.7% in the groups of patients with and without gene VHL alteration, respectively. Progression-free survival was 47.6 and 57.1%, respectively (p=0.619), relapse-free survival — 63.6 and 45.5%, respectively (p=0.682), progression was registered in 36.4 and 54.5%, respectively (p=0.682). Gene VHL inactivation had no effect on prognosis of the disease and results of anti-angiogenic therapy.

Full Text

Restricted Access

References

  1. Давыдов М. И., Аксель Е. М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2006 г. Вестн. РОНЦ им. Н. Н. Блохина РАМН 2008; 19 (2, прил. 1): 6—9.
  2. Cheng L., Zhang S., MacLennan G. T. et al. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum. Pathol. 2009; 40: 10—29.
  3. Hansel D. E., Rini B I. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Rev. Anticancer Ther. 2008; 8: 895—905.
  4. Linehan W. M., Walther M. M., Zbar B. The genetic basis of cancer of the kidney. J. Urol. (Baltimore) 2003; 170: 2163—2172.
  5. Linehan W. M., Zbar B., Klausner R. D. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill Companies; 2002. Chapt. 27.
  6. Wood C. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: Combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 2007; 13 (Suppl. 2): 697—702.
  7. Херрингтон С., Макги Дж. Молекулярная клиническая диагностика: Пер. с англ. М.: Мир; 1999.
  8. Smits K. M., Schouten L. J., Dijk B. A. et al. Genetic and epigenetic alterations in the von Hippel—Lindau gene: the influence on renal cancer prognosis. Clin. Cancer Res. 2008; 14: 782—787.
  9. Gallou C., Joly D., Mejean A. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 1999; 13: 464—475.
  10. Choueiri T. K., Vaziri S. A., Jaeger E. et al. Von Hippel—Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. (Baltimore) 2008; 180: 860—866.
  11. Kim J. H., Jung C. W., Cho Y. H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 2005; 13: 859—864.
  12. van Houwelingen K. P., van Dijk B. A., Hulsbergen-van de Kaa C. A. et al. Prevalence of von Hippel—Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands Cohort Study. BMC Cancer 2005; 5: 57.
  13. Yao M., Yoshida M., Kishida T. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl. Cancer Inst. 2002; 94: 1569—1575.
  14. Rini B. I., Jaeger E., Weinberg V. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel—Lindau gene status. Br. J. Urol. Int. 2006; 98 (4): 756—762.
  15. Choueiri T. K., Vaziri S., Rini B. et al., eds. Use of Von Hippel— Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). ASCO. 2007.
  16. Hutson T., Davis I., Machiels J. et al., eds. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. ASCO. 2008.
  17. Herman J. G., Latif F., Weng Y. et al. Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 1994; 91: 9700—9704.
  18. Banks R. E., Tirukonda P., Taylor C. et al. Genetic and epigenetic analysis of von Hippel—Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006; 66: 2000—2011.
  19. Battagli C., Uzzo R. G., Dulaimi E. et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003; 63: 8695—8699.
  20. Dulaimi E., Ibanez de Caceres I., Uzzo R. G. et al. Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res. 2004; 10: 3972—3979.
  21. Hoque M. O., Begum S., Topaloglu O. et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004; 64: 5511—5517.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies